Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Therapy-Related Hematopoietic Neoplasia

Written2020-11Mark A Micale
Departments of Pathology and Laboratory Medicine and Obstetrics & Gynecology Beaumont Health and Oakland University William Beaumont School of Medicine 3601 West Thirteen Mile Rd. Royal Oak, MI 48073

Abstract Despite new treatments for solid tumors and hematolymphoid malignancies, including targeted therapy and immunotherapy, many cancer patients still require more traditional therapies utilizing cytotoxic chemotherapy and conventional ionizing radiation. These treatments can result in significant short-term morbidity and long-term problems, most notably the development of a therapy-related hematopoietic neoplasm. Therapy-related malignancies usually have a poor outcome, and because of this, there is an effort to elucidate the genetic, molecular, and environmental etiology of these diseases. In this paper, the latest research focused on characterizing therapy-related hematopoietic neoplasms and their pathogenetic mechanisms will be presented along with a compilation of the most common cytogenetic and molecular changes associated with these conditions.

Keywords Therapy-related myeloid neoplasm, therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndrome, clonal hematopoiesis of indeterminate potential, clonal selection, therapy-related acute lymphoblastic leukemia

(Note : for Links provided by Atlas : click)


ICD-Topo C420,C421,C424
ICD-Morpho 9920/3 Therapy-related myeloid neoplasms
Atlas_Id 1303

Clinics and Pathology

Etiology A late-term complication of cytotoxic chemotherapy and radiotherapy for the treatment of both malignant and non-malignant conditions is the development of a therapy-related hematopoietic neoplasm. The World Health Organization's (WHO) most recent Classification of Tumors of Hematopoietic and Lymphoid Tissues (2017) recognizes the entity Therapy-Related Myeloid Malignancies to include therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) [Vardiman et al, 2017]. While not currently recognized as a specific WHO entity due to the small number of cases, several recent studies have begun to characterize therapy-related acute lymphoblastic leukemia (t-ALL) as well [Aldoss et al, 2018; Aldoss et al, 2019; Saygin et al, 2019]. For therapy-related myeloid neoplasms (t-MN), the latency period from original diagnosis to development of neoplasia is dependent upon the nature of the primary exposure. For patients that have received radiation or alkylating agent chemotherapy (including classical agents such as cyclophosphamide, alkylating-like agents such as the platinum-based drugs, or nonclassical agents like procarbizine), the latency period is on average five years and is characterized by cytogenetic abnormalities involving chromosomes 5 [ monosomy 5/del(5q)] and 7 [ monosomy 7/del(7q)]. These patients often develop MDS first, which is difficult to treat and quickly progresses to AML with multilineage dysplasia, and is therefore associated with a poor prognosis. The second subtype of t-MN results from exposure to topoisomerase II inhibitors such as irinotecan, doxorubicin, or etoposide. These neoplasms have a shorter latency period, on average 1-2 years, present as AML without a preceding MDS, are associated with rearrangement of the KMT2A (MLL) gene at chromosome 11q23 or RUNX1 (AML1) gene at 21q22.1, and have a more favorable outcome with intensive induction therapy compared with their alkylating-agent counterpart [Churpek et al, 2013; McNerney et al, 2017].
Therapy-related acute lymphoblastic leukemia (t-ALL) is less well characterized than its myeloid counterpart and has a longer latency period (median 7 years) except for those with KMT2A rearrangement, but is otherwise similar in presentation including prior exposure to both cytotoxic and topoisomerase II inhibitors, similar abnormalities of chromosomes 5 and 7, and an inferior outcome [Aldoss et al, 2018].
Epidemiology Therapy-related myeloid neoplasms account for 10-20% of all cases of myeloid malignancy (AML, MDS, and MDS/MPN). In this group, more patients received prior treatment for a solid tumor (70%) versus a hematopoietic neoplasm (30%). While breast and hematolymphoid malignancies (including Hodgkin and non-Hodgkin lymphoma as well as plasma cell myeloma) account for the largest number of primary diagnoses, treatment for most tumors carries a risk of t-MN. Treatments for solid tumors that utilize either alkylating agents, topoisomerase II inhibitors, or platinum at high doses, including bone / soft tissue, testicular, anal, ovarian /gynecological, and brain malignancies, as well as breast, are at highest risk of developing a t-MN [Murthy and Abedin, 2019]. While any age-group can be affected, the incidence of t-MN mirrors the increased risk of malignancy associated with increasing age, with a median age at diagnosis of 64 years, comparable to de novo AML. Adjusting for confounding variables such as high-risk karyotypes, comorbidities, and poor performance status, a study by Granfeldt Ostgard and colleagues (2015) found that t-MN patients 60 years and older had a similar outcome as patients with de novo disease, suggesting that the two diseases may be biologically similar in older patients; however, in younger patients, t-MN should be considered an independent poor prognostic factor.
With better treatments for cancer, survival rates among many cancers is increasing; however, this will likely result in an increased incidence of t-MN as a long-term complication of this success. Presently, chemotherapy increases the risk of t-MN by 4.7-fold as does younger age at the time of exposure. For breast cancer, the use of hematopoietic growth factors, specifically GSF3 (granulocyte colony-stimulating factor G-CSF) to support blood count recovery also increases the relative risk of t-MN. Changes in treatment protocols have led to changes in incidence of t-MN. For Hodgkin lymphoma, the historical treatment plan included alkylating agent-based chemotherapy with or without extended field radiotherapy, resulting in a 2-6.7% incidence of t-MN, with higher rates if maintenance oral-alkylating agent therapy is utilized; however, with modern therapy protocols including limited radiation, the incidence of t-MN has fallen to 0-0.03% after ten year follow-up. In contrast, risk of t-MN has increased for non-Hodgkin lymphoma, especially following allogenic hematopoietic stem cell transplantation [Churpek et al, 2013; McNerney et al, 2017; Vardiman et al, 2017]. Therapy- related myeloid disorders can also occur as the result of treatments for non-malignant conditions such as autoimmune diseases [Zhang and Wang, 2014], after solid organ transplantation [Dharnidharka 2018], and following autologous or allogenic stem cell transplantation for either malignant or non-malignant conditions [Danylesko and Shimoni, 2018; Saygin et al, 2019].
Therapy-related acute lymphoblastic leukemia (t-ALL) is relatively rare, and for this reason has not been well characterized nor is it a recognized WHO entity in the latest revision. When compared with de novo ALL, t-ALL patients are generally older and more often female. Agents used for immunosuppression to treat autoimmune diseases such as rheumatoid arthritis and following solid organ transplantation and stem cell transplantation also increase the risk of therapy-related lymphoproliferations such as lymphoma [Bagg A, 2011; Aldoss I et al, 2018].
T-ALL has not been as well characterized as its myeloid counterpart because of the lack of large data sets, and so, unlike t-MN, t-ALL is not yet considered a specific entity in the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue. The frequency of t-ALL is reported to be 3-9% of all adult ALL cases, compared with 10-20% t-MN among all myeloid neoplasms. As with t-MN, the prognosis of t-ALL is significantly worse than in de novo ALL. Comparable is the latency period from cytotoxic therapy to development of t-ALL, with a shorter period associated with topoisomerase II inhibitors and KMT2A rearrangement as compared with other chemotherapy and radiation. The most common primary malignancies associated with t-ALL include breast cancer (26%), plasma cell myeloma (19%), prostate cancer (13%), and non-Hodgkin lymphoma (11%) [Saygin et al, 2019]. The incidence of t-ALL appears to be higher in females, likely due to the high incidence of breast cancer and the multimodality treatment such patients receive, including chemotherapy, adjuvant chemotherapy, and radiation, resulting in long term survival for many.
Because fewer cases of t-ALL have been reported, no large-scale studies examining the pathogenesis of the disease have been published; however, the causes of t-ALL are thought to be like those of t-MN. The majority of cases are believed to be due, in large part, to prior cytotoxic therapy for a primary malignancy which results in DNA damage. Likely also contributing to the pathogenesis of t-ALL, like t-MN, is inherited predisposition to mutations in DNA repair genes such as BRCA1, BRCA2, TP53, CHEK2, and PALB2. There are also ALL patients with a prior malignancy but without any cytotoxic therapy, suggesting the possibility of two primary malignancies without inherited predisposition [Aldos et al, 2019].
Pathology Genomic mechanisms that are associated with development of t-MN are not mutually exclusive, and more than one pathway may contribute to t-MN. These include inherited predisposition as well as chemotherapy and/or radiation induced: 1) cytogenetic abnormalities, 2) somatic gene abnormalities, 3) clonal selection, and 4) damage to bone marrow microenvironment:
Other features Damage to Bone Marrow Microenvironment. There is growing evidence that alteration of the bone marrow microenvironment (niche) contributes to the development of myeloid malignancies. Bidirectional crosstalk between HSCs and the niche, which includes mesenchymal stromal cells (MSCs) and progeny cells derived from MSCs such as osteoblasts, has been uncovered in recent studies. Aberrant differentiation of MSCs as well as alterations in key signalling pathways within the bone marrow niche, including WNT-β catenin ( CTNNB1) and NOTCH, have been observed in myeloid malignancies. For example, multiple studies using gene expression profiling demonstrated activation of the WNT pathway in MDS, AML, and t-MN positive for the del(5q) chromosome. Canonical WNT signalling is responsible, in part, for regulating hematopoiesis and maintaining bone marrow niche function. Dysregulating the WNT- β-catenin pathway has been correlated with genomic instability and the presence of complex karyotypes [McNerney et al, 2017]. Another study found that in 38% of patients with AML and MDS, most of whom had del(5q)/monosomy 5 and/or del(7q)/monosomy 7, activation of β-catenin in bone marrow osteoblast cells with subsequent increase in NOTCH signalling in HSCs occurred [Kode A et al, 2014].
The effects of cytotoxic therapy on the bone marrow niche are complex and not completely understood, but have been shown to include a pro-inflammatory response with release of cytokines, damage to HSCs by reactive oxygen species released by multipotent stem cells, and remodelling of the bone marrow niche. Studies in both mice and humans have demonstrated that such exposure to cytotoxic agents creates a "malignant" bone marrow microenvironment that supports selection of mutant HSCs at the expense of healthy HSCs. These mutant stem cells often have reduced TP53 function and apoptosis. Clonal expansion then results in a therapy-related malignancy which, not surprisingly, is difficult to treat. [McNerney et al, 2017].
Cytogenetics One of the major pathogenetic mechanisms underlying the development of t-MN is the acquisition of chromosome abnormalities, found in up to 95% of patients. Approximately 70% of these patients possess an unbalanced karyotype while the remaining 30% present a balanced rearrangement(s) [Vardiman et al, 2017]. The abnormalities are similar to those found in de novo disease; however, t-MN is enriched for high-risk cytogenetic markers. The most common unbalanced rearrangements in t-MN involve deletion of a contiguous chromosome region (CCR) on either chromosome 5q or 7q, whereby the genes within the CCR are functionally unrelated but usually deleted as a block. Constitutional examples of such genomic rearrangements include DiGeorge, Williams, and Prader Willi /Angelman syndromes, whereby a single gene in the CCR may be critical, yet deletion of the entire block of genes within the affected chromosome segment is required for the complete phenotype. In myeloid malignancy, efforts to identify a single critical gene within these commonly deleted regions have been generally unsuccessful, because it appears that there may be a number of genes within the deleted regions responsible for the morphological phenotype. While tumor suppressor genes within these regions appear to be haploinsufficient, precluding identification of a second inactivating mutation, minimally deleted region (MDR) mapping has been possible. An MDR on chromosome 5q31.2 is observed in t-MN, de novo AML, and high-risk MDS while an MDR on chromosome 5q32 is associated with the isolated del(5q) in MDS. A large segment of chromosome 5q spanning the breakpoints 5q14 and 5q33 contains 17 genes, including the APC gene which encodes components of the WNT signalling pathway critical for hematopoiesis and leukemogenesis [McNerney et al, 2017]. Other studies have elucidated the role of deletion of chromosome 5q genes in MDS, including RPS14 associated with the anemia observed in del(5q) MDS [Ebert el al, 2008] and Fli1 associated with thrombocytosis [Neuwirtova et al, 2013]. Stengel et al (2016) found that larger chromosome 5q deletions are associated with TP53 gene mutations as well as additional chromosome abnormalities often as part of a complex karyotype (>3 chromosome abnormalities). These include del(3p), gain of chromosome 8, del(11q), del(13q), del(17p)/monosomy 17, loss of chromosomes 18 and 21, and del(20q) [Vardiman et al, 2017]. Loss of TP53 occurring with del(17p)/monosomy 17 generates greater genomic instability resulting in additional chromosome abnormalities. It also appears that the evolution of pre-existing or emerging subclones with TP53 mutation is a good predictor of disease progression in low-risk del(5q) [Lode et al, 2018].
Chromosome 7q contains three MDRs at 7q22, 7q34, and 7q35-q36. Important genes in these regions include the tumor suppressor gene cut-like homeobox 1 (CUX1) at 7q22; pre-mRNA splicing factor LUC7 like 2 (LUC7L2) gene on 7q34; and KMT2C (MLL3) tumor suppressor, enhancer of zeste homolog 2 (EZH2), and cullin 1 (CUL1) genes at 7q35-q36. In addition, an inherited mutation of the sterile alpha motif domain containing protein 9 like (SAMD9L) gene on 7q21.2 predisposes to AML with monosomy 7 [McNerney et al, 2017].
Thirty percent of t-MN patients present balanced chromosome rearrangements, with 10-15% of these cases demonstrating favorable-risk cytogenetic markers t(8;21)(q22;q22), t(15;17) (q22;q21), and less commonly inv(16)(p13q22). In t-MN, while the prognosis associated with these favorable-risk abnormalities is not as good as in de novo AML, it is better than that associated with high-risk markers including del(5q)/monosomy 5, del(7q)/monosomy 7, complex karyotypes, and TP53 gene deletion/mutation. Normal karyotypes are also found in t-MN, although at a lower frequency compared with de novo AML [Vardiman et al, 2017]. Samra et al (2020) explored the prognostic significance of a normal karyotype in t-AML and found that it was associated with an inferior outcome compared with de novo AML; however, this appeared to be largely due to an increased risk of death in remission as opposed to differences in molecular features or relapse risk. Kim et al (2018) found that t-MN patients with a normal karyotype demonstrated better overall survival after allogenic stem cell transplantation compared with patients that possessed other intermediate-risk markers.
Genes Somatic Gene Alterations. Studies have revealed an overlap in t-MN and de novo AML involving the most commonly mutated genes in these two conditions and the pathways/key cellular components these genes code for or regulate, including chromatin modification, transcription factors, signalling proteins, and the spliceosomal complex. Our understanding of the somatic gene alterations that contribute to t-MN has increased through utilization of next generation sequencing (NGS). Wong et al (2015) studied the whole genomes of 22 t-MN patients along with 149 AML and MDS-related genes in another 89 patients. Contrary to their hypothesis that a greater number of somatic mutations would be found in t-MN compared with de novo AML owing to DNA damage resulting from chemotherapy and radiation therapy, they found a similar number of single nucleotide variants, indels, and copy number alterations in both patient groups. The conclusion from this study and that of Ok CY et al (2015) is that treatment-induced DNA damage is not the only or major driver of t-MN.
In the study by Ok and colleagues (2015), distinct differences between de novo MN and t-MN included the higher incidence of mutations in TP53, KIT, WT1, PTPN11, IDH1/2, and EZH2 genes in t-MN, with de novo disease demonstrating a greater number of mutations in NPM1 and FLT3. [Ok CY et al, 2015; Vardiman et al, 2016]. Singhal et al (2019) compared the clinical and mutational characteristics of t-MN and primary MDS and found both similarities and differences in mutational signatures as well as clinical outcomes between t-MN and primary MDS. While the mutation frequency was found to be similar between the two entities, the mutation pattern was different, with TP53 and SRSF2 mutations more frequent in t-MN possibly due to clonal selection and expansion of hematopoietic stem cells with these mutations under genotoxic stress.
Kuzmanovic and colleagues (2019) described two genetic pathways leading to t-MN, one with mutation of the TP53 gene occurring in up to 37% of t-MN and the other associated with chromosome 7 abnormalities and activation of the RAS pathway. Both t-MN and de novo AML with mutated TP53 as the initiating event in many cases, often present the del(5q) chromosome/monosomy 5 (often as part of a complex karyotype) and predict a poorer outcome. [McNerney et al, 2017]. Unlike in primary disease where most TP53 mutations occur in the DNA binding domain, those identified in t-MN are often associated with nuclear trafficking. Sometimes, acquisition of a TP53 mutation occurs as a secondary event, predicting a high likelihood of leukemic transformation. The second genetic pathway in t-MN, occurring in 49% of patients with a poor outcome, involves del(7q) chromosome/monosomy 7 and mutation of a gene that results in activation of the RAS pathway. Monosomy 7/del(7q) can also be observed with del(5q)/monosomy 5 in some cases of t-MN, often as part of a complex karyotype [McNerney et al, 2017].
Clonal Selection. The concept of clonal hematopoiesis of indeterminate potential (CHIP) is a relatively new one, described by Steensma et al in 2015 as the presence of neoplasia-related mutation(s) in a population of hematopoietic cells without morphological evidence of bone marrow disease. While almost 1% of healthy middle-aged individuals are found to carry a clonal molecular or cytogenetic abnormality, that figure increases in people 50-70 years old, with clonal expansion occurring over time. In one study utilizing error-corrected sequencing (which enables the accurate detection of clonal mutations as rare as 0.0003 variant allele frequency), CHIP was identified in 95% (19/20) of healthy individuals aged 50-60 years [Young et al, 2016]. Mutations commonly identified in CHIP are also found in AML, including in epigenetic modifying genes such as DNMT3A, ASXL1, and TET2, along with TP53. Common cytogenetic abnormalities found in patients with CHIP are recurrent cytogenetic markers in myeloid neoplasia as well, including del(11q), del(13q), del(20q), and trisomy 8. Not surprisingly, these individuals have an increased lifetime risk of developing a hematological malignancy. There is now strong evidence that some patients with a t-MN possess a pre-existing (before chemotherapy or radiation) mutation(s) in hematopoietic stem cells (HSCs). Such cells, under the stress of chemotherapy or radiation may be selected for in the pool of both normal and mutant HSCs so that they predominately repopulate the bone marrow over time. Having been selected for their increased fitness under genotoxic stress, neoplastic cells in t-MN are resistant to treatment [McNerney et al, 2017]. Certain mutations identified in CHIP, such as DNMT3A and TET2, are also observed in MDS patients, suggesting that CHIP progresses to MDS in some individuals [Katagiri et al, 2019]. The study by Kuzmanovic and colleagues revealed evidence that approximately half of TP53-mutated t-MN may be CHIP-related, with cytotoxic therapies accelerating the progression from CHIP to t-MN. They also identified a two-fold increase in TP53 double mutants in t-MN versus in primary myeloid neoplasia [Kuzmanovic et al, 2020]. Soerensen et al (2020) demonstrated that there may be value in evaluating for clonal hematopoiesis in stem cells harvested at leukophoresis [prior to autologous stem cell transplant (ASCT)] using a myeloid NGS panel. Their study demonstrated that identification of low variant allele frequencies, along with aberrant CD7 expression in patients with primary non-myeloid malignancy may indicate an increased risk of developing tMN after ASCT.
Prognosis Patients with t-AML that present with favorable cytogenetic markers including t(8;21), inv(16), and t(15;17) can be treated in the same way as those with de novo disease. Intensive induction chemotherapy with the 7+3 regimen followed by consolidation chemotherapy has been the mainstay; however, a newer treatment for induction called CPX-351 (Vyxeos) has been used. CPX-351 is a liposomal encapsulation of daunorubicin and cytarabine in a 1:5 molar ratio. The results of initial studies revealed an increased overall survival in those patients receiving CPX-351 compared to standard 7+3 therapy. CPX-351 is then used in consolidation after remission. For patients who cannot undergo intensive chemotherapy, Venetoclax with hypomethylating agents or low-dose cytarabine have been used in clinical trials. For patients with intermediate-risk cytogenetic markers, intensive or low-intensity chemotherapy followed by hematopoietic stem cell transplant (HSCT) is recommended. In fact, HCST is regarded as the only curative treatment for t-AML, with better overall survival than consolidation chemotherapy. For unfavorable risk cytogenetic markers, including TP53 mutations, t-MN patients should be referred for a clinical trial or HSCT, if possible [Dhakal et al, 2020]. It has been suggested that restoration of a more normal hematopoietic stem cell microenvironment by reducing the inflammation in bone marrow brought on by cytotoxic therapies might alter therapy-related clonal hematopoiesis [Park and Bejar, 2020].


Inherited Predisposition. NGS studies have identified an inherited mutation in a cancer-associated gene in 8.5-12.6% of cancer patients compared with an incidence of 1-2.7% in patients without known cancer [McNerney et al, 2017]. In addition, while many patients with similar primary malignancies and cytotoxic exposures develop a therapy-related neoplasm, some do not. This phenomenon may, at least in part, be explained by the presence of germline DNA variants in genes for detoxification of chemotherapeutic drugs such as GSTP1 and NQ01, as well as genes that function to repair DNA damage, maintain genomic stability, regulate the cell cycle, and control apoptosis. Such variants may increase the susceptibility to develop a therapy-related neoplasm after cytotoxic drug or radiation exposure. Several studies found that breast cancer survivors with t-MN had germline mutations in DNA-damage response genes including BRCA1, BRCA2, TP53, CHEK2, PALB2, and BARD1 [Schulz et al, 2012; Churpek et al, 2016]. The revised WHO Classification also includes an entity for myeloid neoplasms with germline mutations in DDX41 and ANKRD26 genes. It should be noted that second hematopoietic malignancies that occur after the common latency period following cytotoxic therapy may, in fact, not be "therapy-related", but may represent a second primary malignancy due in part to genetic susceptibility [Chua CC et al, 2019; Takahashi K, 2019].
Autoimmune diseases (AD) including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disorders, multiple sclerosis, ankylosing spondylitis, and others are associated not only with an increased risk of lymphoproliferative disorders but myeloid malignancies as well. In a SEER population-based study, a significantly increased risk of either AML or MDS of 1.29 and 1.5, respectively, was found in patients with an AD [Anderson et al, 2009]. The risk of developing a myeloid neoplasm in an AD appears to be based on several factors including shared genetic susceptibilities with polymorphisms in DNA-repair and drug metabolizing genes, treatment exposure (especially to thiopurines, alkylating agents, and topoisomerase inhibitors), chronic bone marrow stimulation, and immune surveillance defects. In addition, rheumatic disease may co-occur with or be a prelude to an underlying hematological malignancy. It should be kept in mind, however, that not all myeloid malignancies that appear in patients with AD are "therapy-related" as some myeloid neoplasms appear in certain AD subtypes in the absence of prior therapy [Boddu et al, 2019].


Note The most commonly identified balanced cytogenetic abnormalities and associated gene rearrangements in t-MN are provided below. The information is abstracted from the Atlas of Genetics and Cytogenetics in Oncology and Haematology:
Cytogenetics Morphological ETV6 gene (12p13) rearrangements:
- t(4;12)(q12;p13) CHIC2 /ETV6: t-AML and t-ALL; B-cell ALL cases seem to have a more distal breakpoint in 4q13 or 4q21; Median survival is poor, possibly one year.
-t(7;12)(p15;p13), t(12;20)(p13;q11)
- t(12;22)(p13;q12) ETV6/ MN1: t-MN; Survival not certain due to small number of cases, but of nine reported, the survival range was up to 6 years with a median of 2 years.
KMT2A (formally MLL) gene (11q23) rearrangements: t-AML, t-ALL, and biphenotypic acute leukemia; found mainly following treatment with topoisomerase II inhibitors; prior malignancy is variable; prognosis is poor.
- inv(11)(q21q23) KMT2A/ MAML2
- t(1;11)(p32;q23) EPS15 /KMT2A
- t(1;11)(q21;q23) MLLT11 /KMT2A
- t(4;11)(q21;q23) AFF1 /KMT2A
- t(6;11)(q27;q23) AFDN /KMT2A
- t(9;11)(p22;q23) MLLT3 /KMT2A
- t(10;11)(p12;q23) MLLT10 /KMT2A
- t(11;16)(q23;p13.3) KMT2A/ CREBBP
- t(11;17)(q23;q25) KMT2A/ SEPT9
- t(11;19)(q23;p13.3) KMT2A/ MLLT1
- t(11;19)(q23;p13.1) KMT2A/ ELL
RUNX1 (formally AML1) gene (21q22) rearrangements:
- t(8;21)(q22;q22) RUNX1T1 / RUNX1: t-MDS or t-AML; Primary malignancy is solid tumor in 70% of cases; Median survival is 17 months with additional abnormalities and 31 months without additional abnormalities.
- t(3;21)(q26;q22) MECOM /RUNX1: t-MDS and t-AML; Median survival is 8 months.
- t(16;21)(q24;q22) CBFA2T3 /RUNX1: t-AML; Median survival is poor.
RPN1 /MECOM (3q21q26) gene rearrangement:
- inv(3)(q21q26) and t(3;3)(q21;q26): t-MDS or t-AML; primary malignancy is solid tumor in half of cases; Median survival is very poor (7 months).
NUP98 gene (11p15) rearrangements:
- inv(11)(p15q22) and t(11;11)(p15;q22); NUP98/ DDX10: t-MDS and t-AML
- t(7;11)(p15;p15) NUP98/ HOXA9
dic(1;7)(q10;p10) Results in 1q trisomy and 7q monosomy; Half of cases after chemotherapy and radiation; Usually found as the sole abnormality; Breakpoints within α-satellite DNA; Has a distinct gene expression profile associated with gene downregulation supported by a specific epigenetic profile [Fernandez et al, 2019].
t(3;8)(q26.2;q24) MECOM/ MYC rearrangement: Shares similarities with inv(3) GATA2 /MECOM; Dismal outcome.
t(8;16)(p11.2;p13.3) KAT6A / CREBBP rearrangement: Median survival is very poor (5 months); Associated with hemophagocytosis [Xie et al, 2019].
t(9;22)(q34;q11.2) BCR / ABL1 rearrangement: t-AML and t-ALL; primary malignancy is solid tumor in 70% of cases; Median survival is very poor (5 months).
t(15;17)(q22;q21) PML / RARA rearrangement: t-MDS and t-AML; Primary disease is solid tumor in 70% of cases; Median survival is 29 months, although some studies have reported comparable outcomes to de novo acute promyelocytic leukemia [Dhakal et al, 2020].
inv(16)(p13q22) CBFB / MYH11 rearrangement: t-MDS and t-AML; Primary malignancy is solid tumor in 70% of cases; Patients under 55 years appear to have better outcomes; Median survival is 29 months with 45% of patients alive at 5 years (the best survival among subgroups of treatment-related hematopoietic neoplasms with a balanced chromosome rearrangement).
Cytogenetic abnormalities identified in t-ALL are often similar to those observed in t-MN, including monosomal karyotypes; del(5q) and del(7q) chromosomes; KMT2A gene rearrangements; and mutations in genes including DNMT3A, RUNX1, and ASXL1; however, some patients present mutations in genes primarily associated with ALL including CDKN2A IKZF1, FANCL, FANCD2, and BRCA2. The study by Saygin et al, 2019 evaluated patients with t-ALL, de novo ALL (dnALL), and ALL with a prior malignancy but with no history of cytotoxic therapy (pmALL). They found different cytogenetic profiles in t-ALL compared with dnALL and pmALL, with a higher incidence of KMT2A rearrangement (13%) in the t-ALL group compared with 8% in the dnALL group and no cases in the pmALL patients. In addition, 27% of t-ALL patients demonstrated MDS-associated chromosome abnormalities including deletion of chromosomes 5q, 7q, 11q, 13q, 17p, and 20q, along with trisomy 8. By comparison, only 7% of dnALL cases and no cases of pmALL revealed such abnormalities. The t(9;22)(q34;q11.2), the most common abnormality found in adults with de novo ALL, is commonly found in adults with t-ALL as well; however, curiously, 21% of pediatric t-ALL cases in one study presented the Philadelphia chromosome, which is a much higher frequency than what is observed in dnALL in this age group (3%). Cases with the t(9;22) also presented additional chromosome abnormalities at a higher than expected frequency, possibly due to the genetic instability created by prior therapy [Aldoss et al, 2019].
  This bone marrow karyogram is from a 45-year old women with anemia and thrombocytopenia. She is s/p chemotherapy including etoposide for lung cancer completed 34 months ago. Based on these findings and those of morphological and flow cytometric evaluation, the patient was diagnosed with t-AML. The karyotype is: 46,XX,t(16;21)(q24;q22).
  This bone marrow karyogram is from an 84-year old women with macrocytic anemia. She is s/p chemotherapy for breast cancer completed 49 months ago. Based on these findings and those of morphological and flow cytometric evaluation, the patient was diagnosed with t-MDS. The karyotype is: 46,XX,inv(3)(q21q26).

Genes involved and Proteins

Note The information provided below was abstracted from GeneCards® and the NCBI Reference Sequence Database (RefSeq).
Gene NameANKRD26 (Ankyrin repeat domain 26)
Location 10p12.1
Protein This gene encodes a protein containing N-terminal ankyrin repeats that function in protein-protein interactions.
Gene NameAPC (APC regulator of WNT signaling pathway, adenomatous polyposis coli)
Location 5q22.2
Protein This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway as well as being involved in cell migration and adhesion, transcriptional activation, and apoptosis.
Gene NameASXL1 (ASXL transcriptional regulator 1)
Location 20q11.21
Protein The gene encodes a protein which is a member of the Polycomb group of proteins that are necessary for the maintenance of stable repression of homeotic and other loci. The protein is thought to disrupt chromatin in localized areas, enhancing transcription of certain genes while repressing the transcription of other genes.
Gene NameBARD1 (BRCA1-associated RING domain 1)
Location 2q35
Protein This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1, it shares homology with the two most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression.
Gene NameBRCA1 (BRCA1 DNA repair associated)
Location 17q21.31
Protein This gene encodes a protein that plays a role in maintaining genomic stability, specifically the homologous recombination pathway for double-strand DNA repair. It, therefore, acts as a tumor suppressor. The protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). It, therefore, plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.
Gene NameBRCA2 (BRCA2 DNA repair associated)
Location 13q13.1
Protein Both BRCA1 and BRCA2 tumor suppressors are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair.
Gene NameCDKN2A (Cyclin dependent kinase inhibitor 2A)
Location 9p21.3
Protein This gene encodes protein isoforms including, p16INK4A and p14ARF, that function as negative regulators of the cell cycle by inhibiting CDK4 kinase to inhibit cell cycle G1 progression. CDKN2A loss often occurs together with activating mutations of NOTCH1.
Gene NameCHEK2 (Checkpoint kinase 2)
Location 22q12.1
Protein The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the protein prevents entrance into mitosis, stabilizes TP53 leading to cell cycle arrest in G1, and phosphorylates BRCA1, allowing it to restore survival after DNA damage.
Gene NameCUL1 (Cullin 1)
Location 7q36.1
Protein This gene encodes a core component of multiple cullin-RING-based SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes. These mediate the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. Among its related pathways are downstream signaling events of B Cell Receptor (BCR) and WNT.
Gene NameCUX1 (Cut like homeobox 1)
Location 7q22.1
Protein The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins which regulates gene expression, morphogenesis, and differentiation. It may also play a role in cell cycle progression.
Gene NameDDX41 (DEAD-Box helicase 41)
Location 5q35.3
Protein DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure, such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Some members of the DEAD box protein family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. The protein encoded by this gene is a member of the DEAD box protein family and interacts with several spliceosomal proteins.
Gene NameDNMT3A (DNA methytransferase 3 alpha)
Location 2p23.3
Protein This gene encodes a DNA methyltransferase that is thought to function in de
Gene NameEZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
Location 7q36.1
Protein This gene encodes a member of the Polycomb-group (PcG) family and may play a role in the hematopoietic and central nervous systems. PcG family members form multimeric protein complexes which are involved in maintaining the transcriptional repressive state of genes over successive cell generations.
Gene NameFANCD2 (FA complementation group D2)
Location 3p25.3
Protein This gene encodes a ubiquitin ligase protein that is a member of the Fanconi anemia complementation group (FANC), specifically the protein for complementation group D2. This protein is monoubiquinated in response to DNA damage, resulting in its localization to nuclear foci with other proteins (BRCA1 and BRCA2) involved in homology-directed DNA repair.
Gene NameFANCL (FA complementation group L)
Location 2p16.1
Protein This gene encodes a ubiquitin ligase protein that is a member of the Fanconi anemia complementation group (FANC), specifically the protein for complementation group L that mediates monoubiquitination of FANCD2 and FANCI.
Gene NameFLI1 (FLi1 proto-oncogene, ETS transcription factor)
Location 11q24.3
Protein This gene encodes a transcription factor containing an ETS DNA-binding domain.
Gene NameFLT3 (Fms related receptor tyrosine kinase 3)
Location 13q12.2
Protein This gene encodes a receptor tyrosine kinase that regulates hematopoiesis. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. This phorylation activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow.
Gene NameGSTP1 (Glutathione S-transferase Pi 1)
Location 11q13.2
Protein Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. The protein encoded by this gene is thought to play a role in xenobiotic metabolism and to play a role in susceptibility to cancer.
Gene NameIDH1 (Isocitrate dehydrogenase 1) and IDH2 (Isocitrate dehydrogenase 2)
Location IDH1-2q34, IDH2-15q26.1
Protein The proteins encoded by these genes are the NADP(+)-dependent isocitrate dehydrogenases found in cytoplasm and peroxisomes. They catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate and so play a role in metabolism and energy production.
Gene NameIKZF1 (IKAROS family zinc finger 1)
Location 7p12.2
Protein This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation.
Gene NameKIT (KIT proto-oncogene, receptor tyrosine kinase)
Location 4q12
Protein This gene encodes the human homolog of the proto-oncogene C-KIT which was originally identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. This tyrosine-protein kinase acts as a cell-surface receptor for the cytokine KITLG (SCF) and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways.
Gene NameKMT2A (Lysine methyltransferase 2A; mixed lineage leukemia) (MLL)
Location 11q23.3
Protein This gene encodes a transcriptional coactivator protein that plays an essential role in regulating gene expression during early development and hematopoiesis. One of its conserved domains, SET, is responsible for histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation.
Gene NameKMT2C (lysine methyltransferase 2C) (MLL3)
Location 7q36.1
Protein This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a nuclear protein which is a member of the NCOA6 (ASC-2) complex (ASCOM) that possesses histone methylation activity and is involved in transcriptional coactivation.
Gene NameLUC7L2 (LUC7 like 2, pre-mRNA splicing factor)
Location 7q34
Protein The protein encoded by this gene may be involved in the recognition of non-consensus splice donor sites in association with the U1 snRNP spliceosomal subunit.
Gene NameNPM1 (Nucleophosmin 1)
Location 5q35.1
Protein The protein encoded by this gene is involved in centrosome duplication, protein chaperoning, and cell proliferation. It shuttles between the nucleolus, nucleus, and cytoplasm to chaperone ribosomal proteins and core histones from the nucleus to the cytoplasm. It also sequesters the tumor suppressor ARF in the nucleolus, protecting it from degradation until it is needed.
Gene NameNQO1 (NAD(P)H quinone dehydrogenase 1)
Location 16q22.1
Protein This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. Its enzymatic activity prevents the reduction of quinones that lead to production of radical oxygen species that damage DNA.
Gene NamePALB2 (Partner and localizer of BRCA2)
Location 16p12.2
Protein This gene encodes a protein that may function in tumor suppression by binding to and co-localizing with BRCA2 protein in nuclear foci, permitting the stable intranuclear localization and accumulation of BRCA2.
Gene NamePTPN11 (Protein tyrosine phosphatase non-receptor type 11)
Location 12q24.13
Protein The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration.
Gene NameRPS14 (Ribosomal protein S14)
Location 5q33.1
Protein This gene encodes a ribosomal protein that is a component of the 40S subunit of ribosomes.
Gene NameRUNX1 (RUNX family transcription factor 1) (AML1)
Location 22q22.12
Protein Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene is the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis.
Gene NameSAMD9L (Sterile alpha motif domain containing 9 like)
Location 7q21.2
Protein This gene encodes a cytoplasmic protein that acts as a tumor suppressor but also plays a key role in cell proliferation.
Gene NameSRSF2 (Serine and arginine rich splicing factor 2)
Location 17q25.2
Protein The protein encoded by this gene is a member of the serine/arginine (SR)-rich family of pre-mRNA splicing factors which constitute part of the spliceosome. In addition to being critical for mRNA splicing, the SR proteins have also been shown to be involved in mRNA export from the nucleus and in translation.
Gene NameTET2 (Tet methylcytosine dioxygenase 2)
Location 4q24
Protein The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine and is involved in myelopoiesis.
Gene NameTP53 (Tumor protein p53)
Location 17p13.1
Protein This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, and metabolic changes.


Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization?
Aldoss I, Douer D, Pullarkat V
Blood Rev 2019 Sep;37:100584.
PMID 31235377
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O', Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V
Haematologica 2018 Oct;103(10):1662-1668.
PMID 29903756
Risks of myeloid malignancies in patients with autoimmune conditions
Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA
Br J Cancer 2009 Mar 10;100(5):822-8.
PMID 19259097
Therapy-associated lymphoid proliferations
Bagg A
Adv Anat Pathol 2011 May;18(3):199-205.
PMID 21490437
Myeloid disorders after autoimmune disease
Boddu PC, Zeidan AM
Best Pract Res Clin Haematol 2019 Mar;32(1):74-88.
PMID 30927978
Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome
Chua CC, Fleming S, Wei AH
Best Pract Res Clin Haematol 2019 Mar;32(1):3-12.
PMID 30927972
The evolving challenge of therapy-related myeloid neoplasms
Churpek JE, Larson RA
Best Pract Res Clin Haematol 2013 Dec;26(4):309-17.
PMID 24507808
Second Malignancies after Hematopoietic Stem Cell Transplantation
Danylesko I, Shimoni A
Curr Treat Options Oncol 2018 Feb 8;19(2):9.
PMID 29423555
Treatment Strategies for Therapy-related Acute Myeloid Leukemia
Dhakal P, Pyakuryal B, Pudasainee P, Rajasurya V, Gundabolu K, Bhatt VR
Clin Lymphoma Myeloma Leuk 2020 Mar;20(3):147-155.
PMID 31953046
Comprehensive review of post-organ transplant hematologic cancers
Dharnidharka VR
Am J Transplant 2018 Mar;18(3):537-549.
PMID 29178667
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR
Nature 2008 Jan 17;451(7176):335-9.
PMID 18202658
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes
Fernandez AGL, Crescenzi B, Pierini V, Di Battista V, Barba G, Pellanera F, Di Giacomo D, Roti G, Piazza R, Adelman ER, Figueroa ME, Mecucci C
Leukemia 2019 Oct;33(10):2481-2494.
PMID 30923319
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM
J Clin Oncol 2015 Nov 1;33(31):3641-9.
PMID 26304885
Myeloid malignancies after treatment for solid tumours
Guru Murthy GS, Abedin S
Best Pract Res Clin Haematol 2019 Mar;32(1):40-46.
PMID 30927974
Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma
Katagiri S, Makishima H, Azuma K, Nannya Y, Saitoh Y, Yoshizawa S, Akahane D, Fujimoto H, Ito Y, Velaga R, Umezu T, Ohyashiki JH, Ogawa S, Ohyashiki K
Haematologica 2020 Jul;105(7):e337-e339.
PMID 31699793
Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype
Kim SA, Hong J, Park WC, Shin DY, Koh Y, Kim I, Lee DS, Yoon SS
PLoS One 2018 Dec 31;13(12):e0209800.
PMID 30596716
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S
Nature 2014 Feb 13;506(7487):240-4.
PMID 24429522
Genomics of therapy-related myeloid neoplasms
Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T
Haematologica 2020 Mar;105(3):e98-e101.
PMID 31413096
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P
Haematologica 2018 Apr;103(4):e143-e146.
PMID 29269520
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney ME, Godley LA, Le Beau MM
Nat Rev Cancer 2017 Aug 24;17(9):513-527.
PMID 28835720
Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia
Neuwirtova R, Fuchs O, Holicka M, Vostry M, Kostecka A, Hajkova H, Jonasova A, Cermak J, Cmejla R, Pospisilova D, Belickova M, Siskova M, Hochova I, Vondrakova J, Sponerova D, Kadlckova E, Novakova L, Brezinova J, Michalova K
Ann Hematol 2013 Jan;92(1):11-8.
PMID 22965552
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA
Leuk Res 2015 Mar;39(3):348-54.
PMID 25573287
Clonal hematopoiesis in cancer
Park SJ, Bejar R
Exp Hematol 2020 Mar;83:105-112.
PMID 32044376
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ
Blood Cancer J 2020 May 4;10(5):47.
PMID 32366832
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS
Blood Adv 2019 Dec 23;3(24):4228-4237.
PMID 31869410
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms
Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H
J Med Genet 2012 Jul;49(7):422-8.
PMID 22652532
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D', Andrea RJ, Maciejewski JP, Scott HS, Hahn CN, Hiwase DK
Leukemia 2019 Dec;33(12):2842-2853.
PMID 31089247
Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation
Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, Ebbesen LH, Rosenberg CA, Hokland P, Ludvigsen M, Stidsholt Roug A
Blood Adv 2020 Mar 10;4(5):885-892.
PMID 32150606
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL
Blood 2015 Jul 2;126(1):9-16.
PMID 25931582
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations
Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C
Genes Chromosomes Cancer 2016 Oct;55(10):777-85.
PMID 27218649
Germline polymorphisms and the risk of therapy-related myeloid neoplasms
Takahashi K
Best Pract Res Clin Haematol 2019 Mar;32(1):24-30.
PMID 30927971
Therapy-related myeloid neoplasms
Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baurmann I, Kvasnicka HM
In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissueswerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, LeBeau MM, ; Orazi A, Siebert R (Eds);IARC: Lyon 2017
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley T, Link DC, Wilson RK
Nature 2015 Feb 26;518(7540):552-555.
PMID 25487151
Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults
Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G
Ann Hematol 2019 May;98(5):1149-1157.
PMID 30759270
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young AL, Challen GA, Birmann BM, Druley TE
Nat Commun 2016 Aug 22;7:12484.
PMID 27546487
A focused review of hematopoietic neoplasms occurring in the therapy-related setting
Zhang L, Wang SA
Int J Clin Exp Pathol 2014 Jun 15;7(7):3512-23.
PMID 25120730


This paper should be referenced as such :
Micale MA
Therapy-Related Hematopoietic Neoplasia;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version :

Other genes implicated (Data extracted from papers in the Atlas) [ 3 ]


External links

arrayMap (UZH-SIB Zurich)Morph ( 9920/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 16:37:36 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us